(AOF) – Aelis Farma announces cash flow of 20.2 million euros as of December 31, 2023, confirming its financial visibility until the end of 2025. The biotech specializing in the development of treatments for brain diseases posts a net loss of 5.07 million euros compared to 14.28 million in 2022. Aelis Farma plans to announce the effectiveness results of the phase 2b study with AEF0117 after the summer of 2024. At the end of these results, the Indivior group could exercise its license option triggering the payment of a license fee of $100 million.
Aelis Farma has signed a licensing contract with Indivior, “leader in addiction treatment”.
The biotech envisages up to 340 million additional payments, conditional on the achievement of development, regulatory and commercial milestones, as well as royalties on net sales of AEF0117 of between 12% and 20%.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
